NASDAQ:EPOC - Epocrates Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $11.73 0.00 (0.00 %) (As of 07/20/2018 04:00 PM ET)Previous Close$11.73Today's RangeN/A52-Week Range$6.90 - $11.97VolumeN/AAverage Volume228,735 shsMarket Capitalization$291.75 millionP/E RatioN/ADividend YieldN/ABetaN/A Company ProfileFinancialsEarnings HistoryHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Epocrates, Inc. (Epocrates) is a provider of mobile drug reference tools and electronic health records to healthcare professionals and interactive services to the healthcare industry. As of December 31, 2011, its user network consists of well over one million healthcare professionals, including approximately 340,000, or more than 50% of United States physicians. The Company offers its products on major United States mobile platforms, including Apple iOS, Android and BlackBerry. Epocrates operates in two segments: Subscriptions and Interactive Services, and Electronic Health Records. It uses brand names include DocAlert, Epocrates, Epocrates Honors, Epocrates ID, Epocrates Lab, Epocrates MedTools, Epocrates Rx, Epocrates Rx Pro, Epocrates Dx, Epocrates QuickSurvey, Epocrates QuickRecruit, Epocrates MedInsight, EssentialPoints and MedCafe. In October 2011, it launched a redesign of the drug reference tool to create a new platform that provides healthcare professionals. Receive EPOC News and Ratings via Email Sign-up to receive the latest news and ratings for EPOC and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryN/A SectorN/A SymbolNASDAQ:EPOC CUSIPN/A Webwww.epocrates.com Phone+1-415-4163500 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous EmployeesN/A Outstanding SharesN/AMarket Cap$291.75 Epocrates (NASDAQ:EPOC) Frequently Asked Questions What is Epocrates' stock symbol? Epocrates trades on the NASDAQ under the ticker symbol "EPOC." What is the consensus analysts' recommendation for Epocrates? 0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Epocrates in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A." Has Epocrates been receiving favorable news coverage? Media coverage about EPOC stock has been trending somewhat negative this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Epocrates earned a media sentiment score of -0.02 on Accern's scale. They also assigned news coverage about the company an impact score of 47.17 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. How do I buy shares of Epocrates? Shares of EPOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Epocrates' stock price today? One share of EPOC stock can currently be purchased for approximately $11.73. How big of a company is Epocrates? Epocrates has a market capitalization of $291.75 million. How can I contact Epocrates? Epocrates' mailing address is 50 Hawthorne, SAN FRANCISCO, CA 94105, United States. The company can be reached via phone at +1-415-4163500. MarketBeat Community Rating for Epocrates (NASDAQ EPOC)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 66 (Vote Outperform)Underperform Votes: 70 (Vote Underperform)Total Votes: 136MarketBeat's community ratings are surveys of what our community members think about Epocrates and other stocks. Vote "Outperform" if you believe EPOC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EPOC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/21/2018 by MarketBeat.com StaffFeatured Article: How do investors use RSI to grade stocks?